Guidance, NICE advice and quality standards in development

Showing 361 to 370 of 385

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]	Technology appraisal guidance	TBC
Type 2 diabetes in adults: management (medicines update)	NICE guideline	19 June 2025
Ublituximab for treating relapsing–remitting multiple sclerosis ID6350	Technology appraisal guidance	TBC
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]	Technology appraisal guidance	TBC
Urinary Tract Infection (recurrent): antimicrobial prescribing	NICE guideline	13 November 2024
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]	Technology appraisal guidance	20 November 2024
Vamorolone for treating Duchenne muscular dystrophy [ID4024]	Technology appraisal guidance	TBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]	Technology appraisal guidance	TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]	Technology appraisal guidance	TBC
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565	Technology appraisal guidance	TBC